Therapies discovered through stem cell research

September 1, 2016

Pushing the boundaries of regenerative medicine

Biopharmadealmakers Nature (2016)

Read full post

March 1, 2016

COMMENTARY: Go parallel in a big way

Dr Diana Hernandez. Drug Discovery News (2016) Vol. 12, Issue 3

Read full post

July 1, 2015

Massively Parallel Combinatorial Screening

Dr Diana Hernandez. Genetic Engineering & Biotechnology News (2015) Vol. 35, No. 13

Read full post

November 9, 2014

A Miracle Cure? We’re working on it

Matthew Goodman. The Sunday Times (2014)

Read full post

December 5, 2011

Stem Cell Differentiation

Dr Lilian Hook. Drug Discovery World (Winter 2011)

Read full post

December 1, 2011

Protocols Promote Stem Cell Progress

Dr Lilian Hook. Drug Discovery & Development (2011)

Read full post

November 15, 2010

Cell Culture Media Screen

Genetic Engineering & Biotechnology News (2010)

Read full post

October 12, 2010

Plasticell launches second generation CombiCultTM screening platform Company wins Frost & Sullivan 2010 European Technology Innovation Award

London, UK, 12 October 2010 Plasticell, the biotechnology company specialising in high throughput screening for stem cell differentiation, announces the launch of its second generation CombicultTM 10,000-Plex Screen capable of rapidly screening up to ten thousand cell culture media combinations.

Read full post

August 2, 2009

Combinatorial Cell Culture™ patent granted in Europe and other regions

London, UK, 2 August 2009. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that patents protecting its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult™), have been granted by the European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore.

Read full post

November 23, 2007

Plasticell closes first institutional financing round

London, UK, 23 November 2007. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced the closing of a ?690,000 financing round involving an institutional investor for the first time.

Read full post